EHA26: BMS touts positive multiple myeloma data for two pipeline candidates

Bristol Myers Squibb (BMS) presented clinical data for two experimental multiple myeloma treatments at the European Hematology Association Congress (EHA) 2026. The first candidate, mezigdomide combined with Kyprolis and dexamethasone, met the primary endpoint of the SUCCESSOR-2 trial by extending median progression-free survival to 18.0 months compared to 8.3 months with Kyprolis alone. The overall response rate was 80.2% with the combination versus 53.4% with Kyprolis monotherapy. The second candidate, CAR-T therapy arlocabtagene autoleucel, achieved a 96% response rate in patients with relapsed or refractory multiple myeloma. Both treatments showed increased toxicity, including neutropenia and infections. The multiple myeloma therapeutics market is expected to grow to $29 billion by 2032.